Skip to content
Scintria
ToolsGrant writerFunding
HomeLiteratureClinical trialsEvidence LabProtocol packData analysisLearnProjectsLibraryReferencesApplications
Start free
ScintriaStart free

Learn / Clinical Research Management / Foundations: ethics, GCP and the drug development pathway

The drug development pathway and trial phases

14 minute read · 6-question quiz

Download this lesson as a colour Word or PDF study guide with the figures and answers. Included in paid plans; reading and quizzes stay free.Sign in

What you will learn

  • Describe the stages from discovery to post-marketing surveillance

  • Distinguish phase I, II, III and IV trials by purpose, size and population

  • Explain the roles of non-clinical studies, regulatory submission and post-approval evidence

Developing a new medicine typically takes ten years or more and costs a very large sum, and most candidates fail. The pathway is staged so that safety is demonstrated before exposure widens.

Before humans

  • Discovery and non-clinical studies: laboratory and animal work to study pharmacology, toxicology, and safe starting doses.
  • Manufacturing to GMP standards, with quality control.
  • Regulatory and ethics approval to start the first human study (an Investigational New Drug or Clinical Trial Application).

Clinical phases

  • Phase I: first in humans, usually 20 to 100 healthy volunteers (or patients for toxic drugs such as cancer therapies). Questions: Is it safe? How is it absorbed, distributed and eliminated? What dose is tolerated?
  • Phase II: a few hundred patients with the disease. Questions: Does it show signs of working? What dose and schedule? What are common side effects? Often divided into IIa (proof of concept) and IIb (dose-finding).
  • Phase III: confirmatory trials in hundreds to thousands of patients, usually randomised and controlled. Questions: Is it effective and safe compared with the standard of care or placebo? These trials form the main basis for marketing approval.
  • Regulatory review and approval: the sponsor submits the full dossier (the common technical document). Regulators assess quality, safety and efficacy and decide whether to authorise.
  • Phase IV (post-marketing): studies after approval to find rare or long-term adverse events and effects in wider populations, plus ongoing pharmacovigilance.
20 to 100Phase I: safety and dose100 to 300Phase II: signs of efficacy300 to 3,000+Phase III: confirm benefitMany thousandsApproval, then Phase IV
Typical participant numbers by phase. Sizes vary widely with the disease and question.

Attrition

Many candidates drop out at each stage because of toxicity, lack of efficacy or commercial reasons. Only a small fraction of medicines entering human trials reach approval, so each phase acts as a filter that spares later participants and patients from ineffective or unsafe products.

Other kinds of trial

  • Bioequivalence studies for generics, comparing absorption with the reference product.
  • Vaccine trials, with immunogenicity and efficacy endpoints.
  • Device and diagnostic studies with their own regulatory pathways.
  • Pragmatic and real-world studies that test effectiveness in routine care.

Worked example: following a malaria candidate through the pathway

A candidate anti-malarial has shown activity in the laboratory and a safe profile in animals.

  • Phase I: 40 healthy adult volunteers receive single, then repeated, doses. Blood levels and safety are tracked. The maximum tolerated dose is found.
  • Phase II: 200 adults with uncomplicated malaria receive different doses. The best dose clears parasites quickly in most patients.
  • Phase III: 1,500 patients, including children, are randomised to the new drug or the standard treatment. The primary endpoint is the PCR-corrected adequate clinical and parasitological response at day 28.
  • Approval: regulators review the dossier and authorise the medicine.
  • Phase IV: monitoring for rare side effects and resistance continues in routine use.

At each stage, an independent committee may stop the study if safety concerns arise.

1Non-clinicalLab and animalstudies2Phase ISafety, dose3Phase IISignal, dose4Phase IIIConfirm benefit5Approval andPhase IVPost-marketingsafety
The development pathway. Each stage must succeed before the next begins.

Phases describe purpose, not just size

A study is classified by its aim. A small bridging study can be phase III in purpose, and a large safety study can be phase I in purpose. Always read the objectives.

Africa needs trials too

Diseases and populations in Africa differ in genetics, co-infections, nutrition and health systems. Evidence from other regions may not transfer. Conducting trials in Africa gives local patients and regulators relevant data, builds capacity and requires strong ethics and community engagement.

Check yourself

For a product you know, say which phase it is in and what question that phase is answering. Name the primary endpoint in plain words.

Summary

  • Medicines move through non-clinical work, phases I to III, regulatory approval and phase IV surveillance.

  • Phase I tests safety and dose, phase II looks for efficacy signals, phase III confirms benefit.

  • Phase IV and pharmacovigilance detect rare and long-term harms after approval.

  • Classification follows purpose; Africa-based trials add relevant evidence and capacity.

Check your understanding

Question 1
1

The main purpose of a phase I trial is to assess:

Question 2
2

Which phase generally provides the main basis for marketing approval?

Question 3
3

Phase IV trials are conducted:

Question 4
4

Phase I trials often enrol:

Question 5
5

Bioequivalence studies are used for:

Question 6
6

A study's phase is best decided by:

Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.

ICH-GCP: the principles and the peopleRegulatory and ethics approvals in Uganda and the region